Suven Life Sciences Ltd. News and Updates

Name: Latest research reports of Suven Life Sciences Ltd. authored by Geojit BNP Paribas and published by - Trendlyne research reports.
Item: Suven Life Sciences Ltd.
Rating: 5
Author: Geojit BNP Paribas

Keep track of all breaking news on Suven Life Sciences Ltd. from all sources in a single place.

Load latest

Suven Life Sciences Ltd.

27 Apr 2020, 11:51AM

240.69

0.30%

Fire mishap at Suven Life Sciences unit in Hyderabad

Business Line

Fire broke out at Jeedimetla facility of drug maker Suven Life Sciences Ltd here on Sunday. Suven Pharmaceuticals experienced a fire incidence occur

Suven Life Sciences Ltd. has gained 87.57% in the last 6 Months

Suven Life Sciences Ltd.

09 Mar 2020

240.69

0.30%

Suven Pharmaceuticals makes a strong listing

Business Line

Demerged company stock jumps 5%

Suven Life Sciences Ltd. has gained 87.57% in the last 6 Months

Suven Life Sciences Ltd.

12 Feb 2020

240.69

0.30%

Suven Life share price locked at upper circuit on potential sale of CRAMS biz

Moneycontrol

There were pending buy orders of 189,223 shares, with no sellers available.

Suven Life Sciences Ltd. has gained 87.57% in the last 6 Months

Suven Life Sciences Ltd.

21 Jan 2020

240.69

0.30%

Suven Life Sciences shares trade ex-demerger, record date on Jan 22

Moneycontrol

The record date for demerger is January 22, which means the person has to have Suven Life's shares in his/her account by end of this day and then he/she will be eligible for shares of CRAMs business.

Suven Life Sciences Ltd. has gained 133.45% in the last 1 Year

Suven Life Sciences Ltd.

21 Jan 2020

240.69

0.30%

Suven Life Sciences

Suven Life Sciences Ltd.

ICICI Securities Limited

The equity shareholders of the company whose names are recorded in the register of members and records of the depositories as a member of the company as on January 22, 2020 will be entitled to allotment of one fully paid up equity share of face value of | 1 each of SPL (resulting company) that will be issued and allotted for every fully paid up equity share of face...

Suven Life Sciences Ltd. has gained 133.45% in the last 1 Year

Suven Life Sciences Ltd.

07 Jan 2020

240.69

0.30%

Suven Life Sciences share price rises 3% on NCLT nod for Scheme of Arrangement

Moneycontrol

The contract research and manufacturing services undertaking (including its respective assets and liabilities) of the company will be transferred to Suven Pharmaceuticals by way of demerger.

Suven Life Sciences Ltd. is trading above all available SMAs

Suven Life Sciences Ltd.

19 Dec 2019

240.69

0.30%

Company news: Suven Life Sciences

Business Line

Suven Life Sciences on Thursday said that the USFDA, after inspecting its facility recently at Pashamylaram, Hyderabad, issued an Establishment Inspec

Suven Life Sciences Ltd. has gained 87.57% in the last 6 Months

Suven Life Sciences Ltd.

02 Dec 2019

240.69

0.30%

Buy Suven Life Sciences with target Rs 387: AnandRathi

Moneycontrol

Considering the lower-than-anticipated RD cost and operating expenses, we raise our FY20e and FY21e EBITDA respectively 16.7% and 22.8%.

Suven Life Sciences Ltd. has gained 87.57% in the last 6 Months

Suven Life Sciences tumbles 20% as SUVN-502 misses target in phase-2 trial

Business Standard | 02 Dec 2019 1 more

Suven Life Sciences Ltd.

22 Nov 2019

240.69

0.30%

Suven Life Sciences share price jumps 4%

Moneycontrol

The company says the phase 2 data for its SUVN 502, a drug for Alzheimer's disease, will be out in a week.

Suven Life Sciences Ltd. has gained 133.45% in the last 1 Year

Suven Life Sciences Ltd.

21 Nov 2019

240.69

0.30%

SUVEN LIFE SCIENCES LTD

Buy: Suven Life Sciences Ltd.

Target

Geojit BNP Paribas

Q2FY20 revenue grew by ~200% YoY on account of higher sales in CRAMS (+186%) and specialty chemicals (currently 2 products) EBITDA & PAT registered a +300% growth each YoY on account of increase in high margin commercial CRAMS sales, lower employee cost & other expenses as a percentage of sales. Clinical trial data on molecule SUVN-502 which got delayed is expected to be available in 3 weeks time and will be presented in CTAD 2019 - Alzheimer Congress at San Diego, USA ....

Suven Life Sciences Ltd. is trading above all available SMAs

Is Suven Life Sciences Ltd. worth buying?

390 Votes:

Buy 80.51%

Sell 13.08%

Hold 6.41%

134.82% Gain from 52W Low

Suven Life Sciences Ltd. News and Updates

Keep track of all breaking news on Suven Life Sciences Ltd. from all sources in a single place.